Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.47 |
| ▸ | GRB2 | P62993 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10042738 | 1.00 | PSMB8 (0.50) | PSMB8PSMB1PSMB2GRB2HDAC3 | |
| SCHEMBL10042652 | 0.92 | GRB2 (0.47) | PSMB8PSMB1PSMB2GRB2 | |
| SCHEMBL10042643 | 0.92 | GRB2 (0.47) | PSMB8PSMB1PSMB2GRB2 | |
| SCHEMBL1109062 | 0.91 | CTSL (0.50) | PSMB8PSMB1PSMB2HDAC3HDAC4 | |
| SCHEMBL10042739 | 0.89 | ATM (0.53) | GRB2 | |
| SCHEMBL1105429 | 0.88 | PSMB8 (0.50) | PSMB8PSMB1PSMB2GRB2HDAC3 | |
| SCHEMBL13607250 | 0.85 | TAS1R3 (0.52) | PSMB8PSMB1PSMB2 | |
| SCHEMBL22526010 | 0.84 | PSMB11 (0.49) | PSMB8PSMB1PSMB2 | |
| SCHEMBL1109060 | 0.83 | SYK (0.50) | PSMB8PSMB1PSMB2 | |
| SCHEMBL10042737 | 0.82 | KLKB1 (0.55) | PSMB8PSMB1PSMB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238399-A1 | METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORS | SIREN BIOTECHNOLOGY, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| US-20250302990-A1 | ENHANCING NON-VIRAL DNA DELIVERY AND EXPRESSION | SPARK THERAPEUTICS, INC. | 2025-10-02 | — | — | US | disclosed |
| WO-2024238399-A1 | METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORS | SIREN BIOTECHNOLOGY, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302990-A1 | ENHANCING NON-VIRAL DNA DELIVERY AND EXPRESSION | STING1, IFNAR1, IRF3 | PSMB8 1678/4885PSMB1 914/4885PSMB2 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.